Activity Dates: 01/30/2020 - 01/29/2023
If you are a pharmacist, nurse practitioner, or other health care professional providing comprehensive medication management for individuals living with psychiatric disorders, we invite you to participate in this course.
The Substance Use Disorders (SUD) Community is hosting a webinar on the topic of ibogaine for detoxification and management of Opioid Use Disorder (OUD). Ibogaine is a psychedelic drug touted for its unique and robust ability to detoxify persons physically & psychologically dependent on opioids. However, ibogaine is regulated as an illicit substance in the United states and is associated with prolongation of the QTc interval, ventricular arrhythmias, and cardiac death. During the webinar, speaker Benjamin Malcolm, PharmD, MPH, BCPP will focus on the rationale for the research and development of ibogaine, the emerging role of spiritual drug experience in the treatment of mental illness and SUDs, the pharmacology of ibogaine, and existing clinical data on ibogaine for OUD.
You will proceed through the following steps to satisfactorily complete this course:
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 7 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Benjamin Malcolm, PharmD, MPH, BCPPView biographical information and disclosures
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Ibogaine, psilocybin, MDMA (3,4-methylendioxymethamphetamine), ketamine
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.